BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 21468006)

  • 21. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
    Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
    J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
    Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
    Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
    Ammour Y; Susova O; Krasnov G; Nikolaeva E; Varachev V; Schetinina Y; Gavrilova M; Mitrofanov A; Poletaeva A; Bekyashev A; Faizuloev E; Zverev VV; Svitich OA; Nasedkina TV
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
    Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
    J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
    Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
    BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNAs and oncolytic viruses.
    Ruiz AJ; Russell SJ
    Curr Opin Virol; 2015 Aug; 13():40-8. PubMed ID: 25863717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.
    Mazzacurati L; Marzulli M; Reinhart B; Miyagawa Y; Uchida H; Goins WF; Li A; Kaur B; Caligiuri M; Cripe T; Chiocca EA; Amankulor N; Cohen JB; Glorioso JC; Grandi P
    Mol Ther; 2015 Jan; 23(1):99-107. PubMed ID: 25200130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic measles virus strains in the treatment of gliomas.
    Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
    Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
    Myers R; Harvey M; Kaufmann TJ; Greiner SM; Krempski JW; Raffel C; Shelton SE; Soeffker D; Zollman P; Federspiel MJ; Blanco M; Galanis E
    Hum Gene Ther; 2008 Jul; 19(7):690-8. PubMed ID: 18576918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy.
    Hikichi M; Kidokoro M; Haraguchi T; Iba H; Shida H; Tahara H; Nakamura T
    Mol Ther; 2011 Jun; 19(6):1107-15. PubMed ID: 21386827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
    Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
    Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.
    Hutzen B; Pierson CR; Russell SJ; Galanis E; Raffel C; Studebaker AW
    BMC Cancer; 2012 Nov; 12():508. PubMed ID: 23134812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
    Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
    Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
    Bach P; Abel T; Hoffmann C; Gal Z; Braun G; Voelker I; Ball CR; Johnston IC; Lauer UM; Herold-Mende C; Mühlebach MD; Glimm H; Buchholz CJ
    Cancer Res; 2013 Jan; 73(2):865-74. PubMed ID: 23293278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
    Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
    Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.